Peer Reviewed: Numerical Simulation of Tablet Coating - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peer Reviewed: Numerical Simulation of Tablet Coating
The authors investigate the tablet-coating process using a combination of different simulation techniques.


Pharmaceutical Technology
Volume 36, Issue 9, pp. 52-55

Conclusion

Advanced numerical-simulation techniques can aid in the development and optimization of pharmaceutical tablet-coating processes. Investigating mixing performance and the resulting residence time distribution of different coating apparatus can be used to increase intra-tablet coating homogeneity. Numerical simulations of the interplay of drying air, spray, and tablet bed were used to examine both local and global coating performance. Computational results showed how the process parameters influence the film quality and coating uniformity. A usual rule-of-thumb is to place the nozzle at about one-third of the tablet bed, measured along the bed surface starting from the top. The study of different spray-nozzle setups showed that in terms of spray loss, following this rule indeed gave the best results. However, aiming the nozzle slightly away from the air inlet could reduce the amount of spray loss. Finally, inter-tablet coating variability was quantified by using the DEM method to determine the effects of tablet flow inside the coater in terms of residence time under the spray.

In addition to helping achieve a mechanistic understanding of the coating process, the computational data can be collected into in-silico design spaces, in which the correlation between critical process parameters and critical quality attributes provide an improved understanding of the design, optimization, and operation of industrial coating devices.

Gregor Toschkoff, Daniele Suzzi, PhD, and Siegfried Adam, PhD, are researchers at the Research Center for Pharmaceutical Engineering (RCPE) in Graz, Austria. Johannes Khinast*, PhD, is director of RCPE and head of the Institute for Process and Particle Engineering, Graz University of Technology, Inffeldgasse 21/a/II 8010 Graz, Austria, tel. +43 316 873 7978,
.

*To whom all correspondence should be addressed.

Submitted: Apr. 15, 2011; Accepted: Jan. 16, 2012.

References

1. A. Kalbag and C. Wassgren, Chem. Eng. Sci. 64 (11), 2705–2717 (2009).

2. D. Suzzi, S. Radl, and J.G. Khinast, Chem. Eng. Sci. 65 (21), 5699–5715 (2010).

3. B. Freireich and C. Wassgren, Chem. Eng. Sci. 65 (3), 1117–1124 (2010).

4. S. Tobiska and P. Kleinebudde, Intl. J. Pharmaceutics 224 (1–2), 141–149 (2001).

5. L. Ho et al., J. Control. Rel., 119 (3), 253–261 (2007).

6. W.R. Ketterhagen, M.T. am Ende, and B.C. Hancock, J. Pharm. Sci. 98 (2), 442–470 (2009).

7. A. Alexander, T. Shinbrot, and F.J. Muzzio, Powd. Tech. 126 (2), 174–190 (2002).

8. G. Toschkoff et al., AIChE J. 58 (2), 399–411 (2012).

9. D. Suzzi et al., Chem. Eng. Sci. 69 (1), 107–121 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here